A common treatment for advanced kidney cancer is the combination of two immunotherapy drugs called Ipilimumab (Yervoy®) and Nivolumab (Opdivo®). These drugs work by reactivating the body’s own immune response to target and destroy cancer cells. These drugs are not yet used for patients with localized kidney cancer.
The current standard of care for patients with localized kidney cancer is surgical removal of the kidney, followed by active surveillance. This means that your doctor will monitor your recovery closely with regular tests and scans, but you will not receive any new drugs or therapies until there are signs that your cancer has returned.
This study will investigate whether the combination of Nivolumab and Ipilimumab can benefit patients with localized kidney cancer. Specifically, whether the combination is able to delay or prevent cancer from returning in patients who have recently had their kidney removed.
There will be two groups of patients in this study; one group will get Nivolumab and Ipilimumab, while the other group will get the standard of care therapy (the control group). Many clinical trials include a control group so that researchers can tell whether the effect is due to the treatment, or just reflects the natural behaviour of the tumour. A placebo will be administered to the control group so that neither you nor the researchers will know which group you are in.
- Clear cell kidney cancer (incl. sarcomatoid features)
- Cancer must be localized to the kidney, with no spread to other parts of the body
- The kidney was removed within 4-12 weeks of starting the trial
Additional eligibility criteria will apply. Please speak to your doctor.
Find out more about this study.
|Hospital / Cancer Centre||Principal Investigator||Location||Trial Status|
|Hospital / Cancer CentreBC Cancer Agency||Principal Investigator||LocationVancouver, BC||Trial StatusRecruiting|
|Hospital / Cancer CentreHôpital Notre-Dame du CHUM||Principal Investigator||LocationMontréal, QC||Trial StatusRecruiting|
|Hospital / Cancer CentreHôpital régional de Rimouski||Principal Investigator||LocationRimouski, QC||Trial StatusRecruiting|
|Hospital / Cancer CentreR.S. McLaughlin Durham Regional Cancer Centre||Principal Investigator||LocationOshawa, ON||Trial StatusRecruiting|
|Hospital / Cancer CentrePrincess Margaret Cancer Centre||Principal Investigator||LocationToronto, ON||Trial StatusRecruiting|
|Hospital / Cancer CentreSaint John Regional Hospital||Principal Investigator||LocationSaint John, NB||Trial StatusRecruiting|